EZH2 and small cell lung carcinoma: Recently, improved molecular understanding has brought new promising opportunities for SCLC treatment, and several inhibitors targeting MYC (Mollaoglu et al, 2017), DLL3 (Jaspers et al, 2023), EZH2 (Gardner et al, 2017), LSD1 (Chen et al, 2022a) and CDK7 (Zhang et al, 2020) have entered clinical trials.